Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.50 |
| ▸ | AURKA | O14965 | 3/20 | 0.45 |
| ▸ | TTK | P33981 | 3/20 | 0.45 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.45 |
| ▸ | INCENP | Q9NQS7 | 3/20 | 0.45 |
| ▸ | PIM1 | P11309 | 1/20 | 0.42 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.42 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.40 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.40 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | VCP | P55072 | 1/20 | 0.40 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | CAMK2D | Q13557 | 3/20 | 0.39 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | CCNC | P24863 | 1/20 | 0.38 |
| ▸ | CDK8 | P49336 | 1/20 | 0.38 |
| ▸ | KMO | O15229 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5396177 | 0.86 | AURKA (0.61) | PDPK1AURKATTKAURKBINCENP | |
| SCHEMBL5390965 | 0.77 | AURKA (0.50) | AURKA | |
| SCHEMBL5396920 | 0.76 | CDC7 (0.49) | PIM1MKNK2AKT3GSK3B | |
| SCHEMBL28620138 | 0.76 | NOTUM (0.53) | NOTUMCCNCCDK8KMO | |
| SCHEMBL5392838 | 0.76 | AURKA (0.50) | PDPK1AURKATTKAURKBINCENP | |
| SCHEMBL29891398 | 0.76 | NOTUM (0.53) | NOTUMCCNCCDK8KMO | |
| SCHEMBL4851198 | 0.75 | PIK3CG (0.58) | AURKATTKAURKBINCENPPIK3CA | |
| SCHEMBL5406903 | 0.75 | AURKA (0.41) | AURKANOTUM | |
| SCHEMBL27599451 | 0.74 | MAPK1 (0.38) | AURKAGSK3B | |
| SCHEMBL5403837 | 0.72 | AURKA (0.38) | AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1363906-B1 | HETEROCYCLIC INHIBITORS OF ERK2 AND USES THEREOF | VERTEX PHARMA (US) | 2015-07-15 | — | — | EP | claimed |
| CN-100534991-C | Heterocyclic inhibitors of ERK 2 and uses thereof | VERTEX PHARMA (US) | 2009-09-02 | — | — | CN | claimed |
| US-6743791-B2 | ANTICANCER AGENTS; ANTIINFLAMMATORY AGENTS | VERTEX PHARMACEUTICALS INCORPORATED | 2004-06-01 | — | — | US | claimed |
| CN-1494541-A | heterocyclic inhibitors of ERK2 and uses thereof | ��̩��˹ҩ��ɷ�����˾ | 2004-05-05 | — | — | CN | claimed |
| EP-1363906-A2 | HETEROCYCLIC INHIBITORS OF ERK2 AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2003-11-26 | — | — | EP | claimed |
| US-20030092714-A1 | Heterocyclic inhibitors of ERK2 and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2003-05-15 | — | — | US | claimed |
| WO-2002064586-A2 | HETEROCYCLIC INHIBITORS OF ERK2 AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-08-22 | — | — | WO | claimed |
| EP-1363906-B1 | HETEROCYCLIC INHIBITORS OF ERK2 AND USES THEREOF | VERTEX PHARMA (US) | 2015-07-15 | — | — | EP | disclosed |
| CN-100534991-C | Heterocyclic inhibitors of ERK 2 and uses thereof | VERTEX PHARMA (US) | 2009-09-02 | — | — | CN | disclosed |
| US-20070265263-A1 | Heterocyclic inhibitors of ERK2 and uses thereof | CAO JINGRONG | 2007-11-15 | — | — | US | disclosed |
| US-7253187-B2 | Heterocyclic inhibitors of ERK2 and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-08-07 | — | — | US | disclosed |
| US-20040229875-A1 | Heterocyclic inhibitors of ERK2 and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2004-11-18 | — | — | US | disclosed |
| CN-1494541-A | heterocyclic inhibitors of ERK2 and uses thereof | ��̩��˹ҩ��ɷ�����˾ | 2004-05-05 | — | — | CN | disclosed |
| EP-1363906-A2 | HETEROCYCLIC INHIBITORS OF ERK2 AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2003-11-26 | — | — | EP | disclosed |
| WO-2002064586-A2 | HETEROCYCLIC INHIBITORS OF ERK2 AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265263-A1 | Heterocyclic inhibitors of ERK2 and uses thereof | MAPK1, MAPK3, MAPKAPK2 | PDPK1 255/4885AURKA 3692/4885TTK 408/4885 |
| US-20040229875-A1 | Heterocyclic inhibitors of ERK2 and uses thereof | MAPK1, MAPK3, MAP2K2 | PDPK1 166/4885AURKA 1989/4885TTK 128/4885 |
| US-20030092714-A1 | Heterocyclic inhibitors of ERK2 and uses thereof | MAPK1, MAPK3, MAP2K2 | PDPK1 166/4885AURKA 1989/4885TTK 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.